Abstract
Dacomitinib is a second-generation epidermal growth factor receptor (EGFR) Tyrosine Kinase Inhibitor targeted for EGFR sensitizing mutations in patients with non-small cell lung cancer (NSCLC). The efficacy of dacomitinib in patients with advanced NSCLC harboring EGFR mutation was shown in ARCHER 1050. However, data on efficacy of dacomitinib in real-world remain rare.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
